Drug Price Cuts Could Be Option For New Korean President
This article was originally published in PharmAsia News
Executive Summary
Whoever wins the Dec. 19 presidential election in Korea is expected to consider another round of drug prices cuts as a way to pay for expanded health care coverage.
You may also be interested in...
Korea Targets Biologics, Devices, Health Care Among Economic Growth Projects For Next Decade
SEOUL - South Korean President Lee Myung-bak named "17 new growth engines" at a science and technology council meeting at his office in Seoul Jan. 13. Expected to spearhead the country's economic growth for the next 10 years, of those 17 economic growth engines, the Korean government targeted biologics, medical devices and global health care among the national priorities
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.